The Latest Advances
Topical Treatments
Topical treatments are often the first line of treatment for vitiligo. Topical corticosteroids and calcineurin inhibitors, such as tacrolimus, are commonly used to reduce inflammation and promote repigmentation. These treatments can be particularly effective for small areas of depigmented skin.
A more recent development in topical treatments is Opzelura (ruxolitinib), a cream containing a Janus kinase (JAK) inhibitor. JAK inhibitors work by blocking Janus kinase enzymes, which are involved in inflammatory signaling pathways that contribute to depigmentation in vitiligo. Applied directly to the skin, Opzelura offers a targeted approach to treating affected areas. It is available by prescription only, and treatment must be initiated and monitored by a physician experienced in diagnosing and managing non-segmental vitiligo.
Phototherapy
Phototherapy, particularly narrowband ultraviolet B (NB-UVB) therapy, is a well-established treatment option for vitiligo. This method uses specific wavelengths of light to stimulate melanocytes and encourage repigmentation. Patients typically undergo phototherapy sessions under medical supervision several times a week over several months to achieve significant results.
Systemic Treatments
For more severe cases of vitiligo, systemic treatments may be necessary. Oral corticosteroids and immunosuppressive medications are sometimes prescribed to help control the autoimmune processes underlying vitiligo. However, these treatments can have significant side effects and must be used under strict medical supervision.
Promising New Therapies
Ongoing research has highlighted several promising new therapies for vitiligo. Among them, treatments based on Janus kinase (JAK) inhibitors have shown particular promise. These medications target signaling pathways involved in autoimmune responses and may offer additional therapeutic options for patients who do not respond adequately to conventional treatments.
Integrating Natural Approaches
In addition to medical treatments, some patients explore natural approaches to complement their existing care plans. It is essential to consult a dermatologist before starting any new treatment to assess its potential effectiveness, safety, and compatibility with ongoing therapies.
Introducing GliSODin V-SOD
GliSODin V-SOD is a formula containing the patented GliSODin ingredient, developed to support the oral delivery of superoxide dismutase (SOD).
The formula combines a melon extract rich in superoxide dismutase (SOD) with a wheat protein (gliadin), which helps protect SOD during digestion and supports its delivery to the intestinal environment. This combination is designed to preserve SOD activity and support the body's antioxidant defenses.
A randomized, placebo-controlled study evaluated the effects of oral superoxide dismutase (GliSODin) combined with phototherapy in patients with non-segmental vitiligo.
Conducted by Professor Thierry Passeron and published in 2021 in the Journal of the European Academy of Dermatology and Venereology, the study reported 20% repigmentation of vitiligo patches after six months of treatment combining UVB phototherapy and GliSODin V-SOD, compared with 9% in the group receiving UVB phototherapy alone.
Find more information about GliSODin V-SOD here.
It is important to note that GliSODin V-SOD should not be used as a standalone treatment but rather as a complement to treatment prescribed by a dermatologist. Its use as part of a comprehensive care plan, under the supervision of a healthcare professional, may provide additional support alongside established treatments.
For more information about vitiligo treatments, you can consult the international guidelines for vitiligo management, available here.
